PMID- 37544346
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20230918
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 318
IP  - Pt B
DP  - 2024 Jan 10
TI  - Fuzheng Huayu recipe alleviates liver fibrosis via inhibiting NLRP3 inflammasome 
      activation in macrophages.
PG  - 117001
LID - S0378-8741(23)00869-3 [pii]
LID - 10.1016/j.jep.2023.117001 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Fuzheng Huayu recipe (FZHY) is a commonly used 
      Traditional Chinese Medicine formula for treating liver fibrosis in clinical 
      settings. Despite its widespread use, the specific curative effects and 
      underlying pharmacological mechanisms of FZHY in treating liver fibrosis are not 
      yet fully understood. AIM AND STUDY: This study aims to investigate the 
      antifibrotic mechanism of FZHY treatment by exploring its effects on the 
      activation of NOD-like receptor protein 3 (NLRP3) inflammasome in macrophages. 
      MATERIALS AND METHODS: In order to investigate the impact of FZHY on the 
      activation and priming of NLRP3 inflammasome in clinical trials and animal 
      experiments using immunohistochemistry and Western blotting. Twenty-four C57BL/6 
      mice were used to induce liver fibrosis by feeding a diet that contained 
      3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). To study inflammasome function, 
      Lipopolysaccharide (LPS)/adenine triphosphate (ATP) induced NLRP3 inflammasome 
      activation was induced in bone marrow-derived macrophages (BMDMs) isolated from 
      wild mice. The effects of macrophage NLRP3 inflammasome activation on the 
      function of hepatic stellate cells (HSCs) were explored by treating primary HSCs 
      with preconditioned media from BMDMs culture. RESULTS: FZHY treatment resulted in 
      the downregulation of NLRP3 protein expression and inhibition of its priming and 
      activation in both human fibrotic livers and DDC-induced liver fibrosis. 
      Furthermore, FZHY was observed to block the activation of the NLRP3 inflammasome 
      pathway, which can lead to excessive inflammatory cytokine release in 
      supernatants and cell lysates in response to LPS and ATP. Lastly, treatment with 
      FZHY was able to inhibit the activation of HSCs induced by supernatants from 
      macrophages. CONCLUSIONS: FZHY has been shown to potentially prevent NLRP3 
      inflammasome activation in macrophages which can result in the suppression of 
      HSCs activation. Ultimately, these effects may lead to the improvement of liver 
      fibrosis. The ability of FZHY to act on this novel mechanism represents an 
      important aspect of its therapeutic potential for liver fibrosis.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Ping, Dabing
AU  - Ping D
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China.
FAU - Qi, Jingshu
AU  - Qi J
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China.
FAU - Li, Meng
AU  - Li M
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China.
FAU - Sun, Xin
AU  - Sun X
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China.
FAU - Peng, Yuan
AU  - Peng Y
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: 
      pengyuan1026@126.com.
FAU - Liu, Chenghai
AU  - Liu C
AD  - Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai Key Laboratory 
      of Traditional Chinese Clinical Medicine, Shanghai, 201203, China; Key Laboratory 
      of Liver and Kidney Diseases, Ministry of Education, Shanghai, 201203, China. 
      Electronic address: chenghailiu@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230806
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (fuzheng huayu)
RN  - 0 (Inflammasomes)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLR Proteins)
RN  - 0 (Lipopolysaccharides)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
SB  - IM
MH  - Mice
MH  - Humans
MH  - Animals
MH  - *Inflammasomes
MH  - *NLR Family, Pyrin Domain-Containing 3 Protein
MH  - NLR Proteins
MH  - Lipopolysaccharides
MH  - Mice, Inbred C57BL
MH  - Liver Cirrhosis/chemically induced/drug therapy/metabolism
MH  - Adenosine Triphosphate
OTO - NOTNLM
OT  - FZHY
OT  - Liver fibrosis
OT  - Macrophages
OT  - NLRP3
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/07 00:42
MHDA- 2023/09/18 12:43
CRDT- 2023/08/06 19:12
PHST- 2023/04/23 00:00 [received]
PHST- 2023/07/26 00:00 [revised]
PHST- 2023/08/02 00:00 [accepted]
PHST- 2023/09/18 12:43 [medline]
PHST- 2023/08/07 00:42 [pubmed]
PHST- 2023/08/06 19:12 [entrez]
AID - S0378-8741(23)00869-3 [pii]
AID - 10.1016/j.jep.2023.117001 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2024 Jan 10;318(Pt B):117001. doi: 10.1016/j.jep.2023.117001. 
      Epub 2023 Aug 6.